BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1051-1056. [PMID: 19406957 DOI: 10.2215/cjn.05931108] [Cited by in Crossref: 200] [Cited by in F6Publishing: 97] [Article Influence: 15.4] [Reference Citation Analysis]
Number Citing Articles
1 Larson DS, Coyne DW. Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease. Kidney Res Clin Pract 2013;32:11-5. [PMID: 26894030 DOI: 10.1016/j.krcp.2013.01.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
2 Fishbane S. Anemia management: a historical perspective. Kidney International Supplements 2021;11:3-7. [DOI: 10.1016/j.kisu.2020.12.004] [Reference Citation Analysis]
3 Belo L, Rocha S, Valente MJ, Coimbra S, Catarino C, Bronze-da-Rocha E, Rocha-Pereira P, do Sameiro-Faria M, Oliveira JG, Madureira J, Fernandes JC, Miranda V, Santos-Silva A. Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients. Ren Fail 2019;41:662-72. [PMID: 31296086 DOI: 10.1080/0886022X.2019.1635893] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Sofroniadou S, Goldsmith D. Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Saf 2011;34:97-115. [PMID: 21247219 DOI: 10.2165/11585040-000000000-00000] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
5 Roger SD, Tio M, Park HC, Choong HL, Goh B, Cushway TR, Stevens V, Macdougall IC. Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis. Nephrology (Carlton) 2017;22:969-76. [PMID: 27699922 DOI: 10.1111/nep.12940] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
6 Haase VH. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial Int 2017;21 Suppl 1:S110-24. [PMID: 28449418 DOI: 10.1111/hdi.12567] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
7 Gaweda AE, Ginzburg YZ, Chait Y, Germain MJ, Aronoff GR, Rachmilewitz E. Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant 2015;30:187-96. [PMID: 24821751 DOI: 10.1093/ndt/gfu104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
8 Hayder ZS, Kareem ZS. Resistin hormone in diabetic kidney disease and its relation to iron status and hepcidin. Int Urol Nephrol 2020;52:749-56. [PMID: 32173772 DOI: 10.1007/s11255-020-02434-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K, Wolf M, Hirakata H. Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci Rep 2019;9:8877. [PMID: 31222044 DOI: 10.1038/s41598-019-45335-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
10 Gavish R, Watad S, Ben-Califa N, Goldberg OJ, Haskin O, Davidovits M, Koren G, Falush Y, Neumann D, Krause I. Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay. Pediatr Nephrol 2018;33:2123-9. [PMID: 30030607 DOI: 10.1007/s00467-018-4016-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Punj S, Ghafourian K, Ardehali H. Iron deficiency and supplementation in heart failure and chronic kidney disease. Mol Aspects Med 2020;75:100873. [PMID: 32753256 DOI: 10.1016/j.mam.2020.100873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes-A Systematic Literature Review. Int J Nephrol 2020;2020:7692376. [PMID: 32665863 DOI: 10.1155/2020/7692376] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Burpee T, Mitchell P, Fishman D, Islam S, Nemeth E, Westerman M, Wessling-Resnick M, Grand RJ. Intestinal ferroportin expression in pediatric Crohn's disease. Inflamm Bowel Dis 2011;17:524-31. [PMID: 20564534 DOI: 10.1002/ibd.21367] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
14 Atkinson MA, Kim JY, Roy CN, Warady BA, White CT, Furth SL. Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort. Pediatr Nephrol 2015;30:635-43. [PMID: 25380788 DOI: 10.1007/s00467-014-2991-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
15 Sun CC, Vaja V, Chen S, Theurl I, Stepanek A, Brown DE, Cappellini MD, Weiss G, Hong CC, Lin HY, Babitt JL. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant 2013;28:1733-43. [PMID: 23345622 DOI: 10.1093/ndt/gfs584] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
16 Masajtis-Zagajewska A, Nowicki M. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Ren Fail 2018;40:700-9. [PMID: 30741616 DOI: 10.1080/0886022X.2018.1535983] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Dignass A, Farrag K, Stein J. Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions. Int J Chronic Dis 2018;2018:9394060. [PMID: 29744352 DOI: 10.1155/2018/9394060] [Cited by in Crossref: 35] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
18 Hsieh YP, Huang CH, Lee CY, Chen HL, Lin CY, Chang CC. Hepcidin-25 negatively predicts left ventricular mass index in chronic kidney disease patients. World J Nephrol 2013; 2(2): 38-43 [PMID: 24175264 DOI: 10.5527/wjn.v2.i2.38] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
19 Wang K, Wu J, Xu J, Gu S, Li Q, Cao P, Li M, Zhang Y, Zeng F. Correction of Anemia in Chronic Kidney Disease With Angelica sinensis Polysaccharide via Restoring EPO Production and Improving Iron Availability. Front Pharmacol 2018;9:803. [PMID: 30108502 DOI: 10.3389/fphar.2018.00803] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
20 Ueda N, Takasawa K. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease. Nutrients 2018;10:E1173. [PMID: 30150549 DOI: 10.3390/nu10091173] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 10.5] [Reference Citation Analysis]
21 Bjørklund G, Peana M, Pivina L, Dosa A, Aaseth J, Semenova Y, Chirumbolo S, Medici S, Dadar M, Costea DO. Iron Deficiency in Obesity and after Bariatric Surgery. Biomolecules 2021;11:613. [PMID: 33918997 DOI: 10.3390/biom11050613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Pratt RD, Grimberg S, Zaritsky JJ, Warady BA. Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis. Pediatr Nephrol 2018;33:2151-9. [PMID: 30003313 DOI: 10.1007/s00467-018-4014-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
23 Oruç Ç, Canpolat N, Pehlivan E, Balcı Ekmekçi Ö, Ağbaş A, Çalışkan S, Sever FL. Anemia after kidney transplantation: Does its basis differ from anemia in chronic kidney disease? Pediatr Transplant 2020;24:e13818. [PMID: 32797673 DOI: 10.1111/petr.13818] [Reference Citation Analysis]
24 van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, Nubé MJ, Penne EL, Gaillard CA, Wetzels JF, Wiegerinck ET, Swinkels DW, Blankestijn PJ, Ter Wee PM; CONTRAST Investigators. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 2012;7:e39783. [PMID: 22808058 DOI: 10.1371/journal.pone.0039783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
25 Xue D, Zhou C, Shi Y, Lu H, He X. Hepcidin as a Biomarker of Impaired Renal Function in Rat Models for Chronic Allograft Nephropathy. Med Sci Monit 2016;22:608-16. [PMID: 26907911 DOI: 10.12659/msm.895375] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Crockett DK, Kushnir MM, Phillips JD, Rockwood AL. Time-of-flight mass spectrometry analysis of the ferroportin-hepcidin binding domain complex for accurate mass confirmation of bioactive hepcidin 25. Clin Chim Acta 2010;411:453-5. [PMID: 19962373 DOI: 10.1016/j.cca.2009.11.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
27 Hanudel MR, Czaya B, Wong S, Rappaport M, Namjoshi S, Chua K, Jung G, Gabayan V, Qiao B, Nemeth E, Ganz T. Enteral ferric citrate absorption is dependent on the iron transport protein ferroportin. Kidney Int 2021:S0085-2538(21)01077-2. [PMID: 34838540 DOI: 10.1016/j.kint.2021.10.036] [Reference Citation Analysis]
28 Girelli D, Trombini P, Busti F, Campostrini N, Sandri M, Pelucchi S, Westerman M, Ganz T, Nemeth E, Piperno A, Camaschella C. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 2011;96:500-6. [PMID: 21173098 DOI: 10.3324/haematol.2010.033449] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
29 Goyal H, Mohanty S, Sharma M, Rani A. Study of anemia in nondialysis dependent chronic kidney disease with special reference to serum hepcidin. Indian J Nephrol 2017;27:44-50. [PMID: 28182038 DOI: 10.4103/0971-4065.179301] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
30 Atkinson MA, Warady BA. Anemia in chronic kidney disease. Pediatr Nephrol 2018;33:227-38. [PMID: 28412770 DOI: 10.1007/s00467-017-3663-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
31 Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, Poli A, Martinelli N, Lupo A, Olivieri O, Girelli D. Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol. 2010;2010:329646. [PMID: 20414466 DOI: 10.1155/2010/329646] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
32 Atkinson MA, Juraschek SP, Bertenthal MS, Detrick B, Furth SL, Miller ER 3rd. Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial. Pediatr Nephrol 2017;32:859-68. [PMID: 28013381 DOI: 10.1007/s00467-016-3563-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
33 Gharekhani A, Khatami MR, Dashti-Khavidaki S, Razeghi E, Abdollahi A, Hashemi-Nazari SS, Mansournia MA. Potential effects of omega-3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients. Daru 2014;22:11. [PMID: 24397938 DOI: 10.1186/2008-2231-22-11] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
34 Röhrig G, Becker I, Polidori MC, Schulz RJ, Noreik M. Association of anemia and hypoalbuminemia in German geriatric inpatients: Relationship to nutritional status and comprehensive geriatric assessment. Z Gerontol Geriatr 2015;48:619-24. [PMID: 25877770 DOI: 10.1007/s00391-015-0872-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
35 Atkinson MA, Furth SL. Anemia in children with chronic kidney disease. Nat Rev Nephrol 2011;7:635-41. [PMID: 21894183 DOI: 10.1038/nrneph.2011.115] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
36 Pham K, Parikh K, Heinrich EC. Hypoxia and Inflammation: Insights From High-Altitude Physiology. Front Physiol 2021;12:676782. [PMID: 34122145 DOI: 10.3389/fphys.2021.676782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica 2013;98:1667-76. [PMID: 24186312 DOI: 10.3324/haematol.2013.084624] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
38 Sofroniadou S, Goldsmith D. Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Saf. 2011;34:97-115. [PMID: 21247219 DOI: 10.2165/11585040] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med. 2012;3:77-85. [PMID: 22973119 DOI: 10.2147/jbm.s29204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 20] [Article Influence: 0.5] [Reference Citation Analysis]
40 Loutradis C, Skodra A, Georgianos P, Tolika P, Alexandrou D, Avdelidou A, Sarafidis PA. Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: A nested case-control study. World J Nephrol 2016; 5(4): 358-366 [PMID: 27458564 DOI: 10.5527/wjn.v5.i4.358] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
41 Maxwell KD, Chuang J, Chaudhry M, Nie Y, Bai F, Sodhi K, Liu J, Shapiro JI. The potential role of Na-K-ATPase and its signaling in the development of anemia in chronic kidney disease. Am J Physiol Renal Physiol 2021;320:F234-42. [PMID: 33356956 DOI: 10.1152/ajprenal.00244.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 D'Angelo G. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res 2013;48:10-5. [PMID: 23589789 DOI: 10.5045/br.2013.48.1.10] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
43 Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Bansal SS, Cronin M, Meier Y, Larroque S, Roger SD, Macdougall IC. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial. PLoS One 2016;11:e0157063. [PMID: 27276035 DOI: 10.1371/journal.pone.0157063] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
44 Ibrahim IA, Mohamad UM, Darweesh HA, Rashad AM. Impact of hepcidin, interleukin 6, and other inflammatory markers with respect to erythropoietin on anemia in chronic hemodialysis patients. Egypt J Intern Med 2014;26:6-14. [DOI: 10.4103/1110-7782.132882] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
45 Silverstein DM. Growth and Nutrition in Pediatric Chronic Kidney Disease. Front Pediatr 2018;6:205. [PMID: 30155452 DOI: 10.3389/fped.2018.00205] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
46 Atkinson MA, Joo S, Sule S. Hepcidin and arterial stiffness in children with systemic lupus erythematosus and lupus nephritis: A cross-sectional study. PLoS One 2019;14:e0214248. [PMID: 30925172 DOI: 10.1371/journal.pone.0214248] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Agarwal AK. Iron metabolism and management: focus on chronic kidney disease. Kidney Int Suppl (2011) 2021;11:46-58. [PMID: 33777495 DOI: 10.1016/j.kisu.2020.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
48 Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010;5:1010-4. [PMID: 20299375 DOI: 10.2215/CJN.08161109] [Cited by in Crossref: 62] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
49 Eguchi A, Mochizuki T, Tsukada M, Kataoka K, Hamaguchi Y, Oguni S, Nitta K, Tsuchiya K. Serum hepcidin levels and reticulocyte hemoglobin concentrations as indicators of the iron status of peritoneal dialysis patients. Int J Nephrol 2012;2012:239476. [PMID: 23193472 DOI: 10.1155/2012/239476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
50 Tomasz G, Ewa W, Jolanta M. Biomarkers of iron metabolism in chronic kidney disease. Int Urol Nephrol 2021;53:935-44. [PMID: 33025407 DOI: 10.1007/s11255-020-02663-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Fung E, Sugianto P, Hsu J, Damoiseaux R, Ganz T, Nemeth E. High-throughput screening of small molecules identifies hepcidin antagonists. Mol Pharmacol 2013;83:681-90. [PMID: 23292796 DOI: 10.1124/mol.112.083428] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
52 Nakayama M, Tani Y, Zhu WJ, Watanabe K, Yokoyama K, Fukagawa M, Akiba T, Wolf M, Hirakata H. Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide. Kidney Int Rep 2018;3:364-73. [PMID: 29725640 DOI: 10.1016/j.ekir.2017.10.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
53 Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823:1434-1443. [PMID: 22306005 DOI: 10.1016/j.bbamcr.2012.01.014] [Cited by in Crossref: 626] [Cited by in F6Publishing: 601] [Article Influence: 62.6] [Reference Citation Analysis]
54 Haase-Fielitz A, Mertens PR, Plass M, Kuppe H, Hetzer R, Westerman M, Ostland V, Prowle JR, Bellomo R, Haase M. Urine hepcidin has additive value in ruling out cardiopulmonary bypass-associated acute kidney injury: an observational cohort study. Crit Care 2011;15:R186. [PMID: 21816077 DOI: 10.1186/cc10339] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
55 Troutt JS, Butterfield AM, Konrad RJ. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J Clin Lab Anal 2013;27:504-10. [PMID: 24218134 DOI: 10.1002/jcla.21634] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
56 Bandach I, Segev Y, Landau D. Experimental modulation of Interleukin 1 shows its key role in chronic kidney disease progression and anemia. Sci Rep 2021;11:6288. [PMID: 33737665 DOI: 10.1038/s41598-021-85778-2] [Reference Citation Analysis]
57 Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011;2011:538-42. [PMID: 22160086 DOI: 10.1182/asheducation-2011.1.538] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 7.6] [Reference Citation Analysis]
58 Röhrig G, Nobbe C, Weiß V, Schulz R. Hepcidin in anaemic geriatric patients with non-dialysis chronic kidney disease (ND-CKD). European Geriatric Medicine 2013;4:221-5. [DOI: 10.1016/j.eurger.2013.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Guan P, Sun ZM, Luo LF, Zhao YS, Yang SC, Yu FY, Wang N, Ji ES. Hydrogen Gas Alleviates Chronic Intermittent Hypoxia-Induced Renal Injury through Reducing Iron Overload. Molecules 2019;24:E1184. [PMID: 30917568 DOI: 10.3390/molecules24061184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Vilela EM, Bastos JA, Fernandes N, Ferreira AP, Chaoubah A, Bastos MG. Treatment of chronic periodontitis decreases serum prohepcidin levels in patients with chronic kidney disease. Clinics (Sao Paulo) 2011;66:657-62. [PMID: 21655762 DOI: 10.1590/s1807-59322011000400022] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
61 McKnight Q, Jenkins S, Li X, Nelson T, Marlier A, Cantley LG, Finberg KE, Fretz JA. IL-1β Drives Production of FGF-23 at the Onset of Chronic Kidney Disease in Mice. J Bone Miner Res 2020;35:1352-62. [PMID: 32154933 DOI: 10.1002/jbmr.4003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
62 Nalado AM, Olorunfemi G, Dix-Peek T, Dickens C, Khambule L, Snyman T, Paget G, Mahlangu J, Duarte R, George J, Naicker S. Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa. BMC Nephrol 2020;21:415. [PMID: 32993549 DOI: 10.1186/s12882-020-02046-7] [Reference Citation Analysis]
63 Lim CT, Yap XH, Chung KJ, Khalid MA, Yayha N, Latiff LA, Goh BL. Predictor of cardiovascular risks in end stage renal failure patients on maintenance dialysis. Pak J Med Sci 2015;31:1300-5. [PMID: 26870086 DOI: 10.12669/pjms.316.8039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
64 Macciò A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi MC, Floris C, Omoto I, Barracca A, Ganz T. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica 2015;100:124-32. [PMID: 25239265 DOI: 10.3324/haematol.2014.112813] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 11.0] [Reference Citation Analysis]
65 Kawamura T, Usui J, Kaneko S, Tsunoda R, Imai E, Kai H, Morito N, Saito C, Nagata M, Yamagata K. Anaemia is an essential complication of ANCA-associated renal vasculitis: a single center cohort study. BMC Nephrol 2017;18:337. [PMID: 29178888 DOI: 10.1186/s12882-017-0754-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
66 Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis. 2010;55:726-741. [PMID: 20189278 DOI: 10.1053/j.ajkd.2009.12.030] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 11.0] [Reference Citation Analysis]
67 Yalcin MM, Altinova AE, Akturk M, Gulbahar O, Arslan E, Ors Sendogan D, Yetkin I, Toruner FB. GDF-15 and Hepcidin Levels in Nonanemic Patients with Impaired Glucose Tolerance. J Diabetes Res 2016;2016:1240843. [PMID: 27642607 DOI: 10.1155/2016/1240843] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
68 Machado SE, Spangler D, Black LM, Traylor AM, Balla J, Zarjou A. A Reproducible Mouse Model of Moderate CKD With Early Manifestations of Osteoblastic Transition of Cardiovascular System. Front Physiol 2022;13:897179. [DOI: 10.3389/fphys.2022.897179] [Reference Citation Analysis]
69 Atkinson MA, White CT. Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. Pediatr Nephrol 2012;27:33-40. [PMID: 21400189 DOI: 10.1007/s00467-011-1832-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
70 Rodríguez-Mortera R, Caccavello R, Hermo R, Garay-Sevilla ME, Gugliucci A. Higher Hepcidin Levels in Adolescents with Obesity Are Associated with Metabolic Syndrome Dyslipidemia and Visceral Fat. Antioxidants (Basel) 2021;10:751. [PMID: 34065056 DOI: 10.3390/antiox10050751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Zaman BA, Rasool SO, Ibrahim NMR, Abdulah DM. HeGRI: A Novel Index of Serum Hepcidin Suppression in Relation to the Degree of Renal Dysfunction among β-Thalassemia Major Patients. Thalassemia Reports 2022;12:2-11. [DOI: 10.3390/thalassrep12010002] [Reference Citation Analysis]
72 Brătescu LO, Bârsan L, Gârneaţă L, Stanciu A, Lipan M, Stancu SH, Mircescu G. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency. Int Urol Nephrol 2014;46:1005-12. [PMID: 24800994 DOI: 10.1007/s11255-014-0696-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
73 Li M, Lan J, Dong F, Duan P. Effectiveness of hypoxia-induced factor prolyl hydroxylase inhibitor for managing anemia in chronic kidney disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2021;77:491-507. [PMID: 33161463 DOI: 10.1007/s00228-020-03037-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Ikeda Y, Horinouchi Y, Hamano H, Hirayama T, Kishi S, Izawa-Ishizawa Y, Imanishi M, Zamami Y, Takechi K, Miyamoto L, Ishizawa K, Aihara KI, Nagasawa H, Tsuchiya K, Tamaki T. Dietary iron restriction alleviates renal tubulointerstitial injury induced by protein overload in mice. Sci Rep 2017;7:10621. [PMID: 28878231 DOI: 10.1038/s41598-017-11089-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
75 Eisenga MF, Dullaart RP, Berger SP, Sloan JH, de Vries AP, Bakker SJ, Gaillard CA. Association of hepcidin-25 with survival after kidney transplantation. Eur J Clin Invest 2016;46:994-1001. [PMID: 27696386 DOI: 10.1111/eci.12682] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
76 Nemeth E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2010;2010:750643. [PMID: 20066043 DOI: 10.1155/2010/750643] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
77 Limm-Chan B, Wesseling-Perry K, Pearl MH, Jung G, Tsai-Chambers E, Weng PL, Hanudel MR. Associations among erythropoietic, iron-related, and FGF23 parameters in pediatric kidney transplant recipients. Pediatr Nephrol 2021. [PMID: 33903951 DOI: 10.1007/s00467-021-05081-0] [Reference Citation Analysis]
78 Zhong Z, Luo D, Luo N, Li B, Fu D, Fan L, Li Z, Chen W, Mao H. Serum Hepcidin-25 and Risk of Mortality in Patients on Peritoneal Dialysis. Front Med (Lausanne) 2021;8:684548. [PMID: 34222290 DOI: 10.3389/fmed.2021.684548] [Reference Citation Analysis]
79 Hanudel MR, Rappaport M, Gabayan V, Jung G, Salusky IB, Nemeth E, Ganz T, Zaritsky J. Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model. Haematologica 2017;102:e85-8. [PMID: 27884972 DOI: 10.3324/haematol.2016.150433] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
80 Chen J, Wang F, Huang S, Liu X, Li Z, Qi A, Liu X, Yi T, Li S. Jian-Pi-Yi-Shen Decoction Relieves Renal Anemia in 5/6 Nephrectomized Rats: Production of Erythropoietin via Hypoxia Inducible Factor Signaling. Evid Based Complement Alternat Med 2019;2019:2807926. [PMID: 30941190 DOI: 10.1155/2019/2807926] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
81 Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631-1634. [PMID: 22935483 DOI: 10.1681/asn.2011111078] [Cited by in Crossref: 352] [Cited by in F6Publishing: 194] [Article Influence: 35.2] [Reference Citation Analysis]
82 Panwar B, McCann D, Olbina G, Westerman M, Gutiérrez OM. Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial. BMC Nephrol 2018;19:35. [PMID: 29426300 DOI: 10.1186/s12882-018-0823-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
83 Lee SW, Kim JM, Lim HJ, Hwang YH, Kim SW, Chung W, Oh KH, Ahn C, Lee KB, Sung SA. Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance. Sci Rep 2017;7:4260. [PMID: 28652624 DOI: 10.1038/s41598-017-04664-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
84 Chand S, Ward DG, Ng ZY, Hodson J, Kirby H, Steele P, Rooplal I, Bantugon F, Iqbal T, Tselepis C, Drayson MT, Whitelegg A, Chowrimootoo M, Borrows R. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. J Nephrol 2015;28:81-8. [PMID: 24687402 DOI: 10.1007/s40620-014-0083-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
85 Lotfi R, Kroll C, Plonné D, Jahrsdörfer B, Schrezenmeier H. Hepcidin/Ferritin Quotient Helps to Predict Spontaneous Recovery from Iron Loss following Blood Donation. Transfus Med Hemother 2015;42:390-5. [PMID: 26733771 DOI: 10.1159/000440825] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
86 Šimetić L, Zibar L. Laboratory use of hepcidin in renal transplant recipients. Biochem Med (Zagreb) 2016;26:34-52. [PMID: 26981017 DOI: 10.11613/BM.2016.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Lee KH, Ho Y, Tarng DC. Iron Therapy in Chronic Kidney Disease: Days of Future Past. Int J Mol Sci 2021;22:1008. [PMID: 33498292 DOI: 10.3390/ijms22031008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Froissart M, Stengel B; NephroTest Study Group. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One 2014;9:e99781. [PMID: 24978810 DOI: 10.1371/journal.pone.0099781] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
89 Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425-4433. [PMID: 21346250 DOI: 10.1182/blood-2011-01-258467] [Cited by in Crossref: 563] [Cited by in F6Publishing: 510] [Article Influence: 51.2] [Reference Citation Analysis]
90 Akchurin O, Sureshbabu A, Doty SB, Zhu YS, Patino E, Cunningham-Rundles S, Choi ME, Boskey A, Rivella S. Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease. Am J Physiol Renal Physiol 2016;311:F877-89. [PMID: 27440777 DOI: 10.1152/ajprenal.00089.2016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
91 Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol 2020;31:456-68. [PMID: 32041774 DOI: 10.1681/ASN.2019020213] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
92 Röhrig G. [Anemia in the aged]. Z Gerontol Geriatr 2018;51:935-46. [PMID: 30498858 DOI: 10.1007/s00391-018-01479-y] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
93 Zughaier SM, Alvarez JA, Sloan JH, Konrad RJ, Tangpricha V. The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J Clin Transl Endocrinol 2014;1:19-25. [PMID: 25097830 DOI: 10.1016/j.jcte.2014.01.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
94 Hanudel MR, Laster ML, Portale AA, Dokras A, Quigley RP, Guzman GAL, Zaritsky JJ, Hayde NA, Kaskel FJ, Mitsnefes MM, Ramirez JA, Imani PD, Srivaths PR, Kogon AJ, Denburg MR, Blydt-Hansen TD, Reyes LZ, Greenbaum LA, Weidemann DK, Warady BA, Elashoff DA, Mendley SR, Isakova T, Salusky IB. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial. Pediatr Nephrol 2022. [PMID: 35237863 DOI: 10.1007/s00467-022-05492-7] [Reference Citation Analysis]
95 Ganz T, Nemeth E. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. Semin Nephrol 2016;36:87-93. [PMID: 27236128 DOI: 10.1016/j.semnephrol.2016.02.001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 18.3] [Reference Citation Analysis]
96 Javard R, Grimes C, Bau-Gaudreault L, Dunn M. Acute-Phase Proteins and Iron Status in Cats with Chronic Kidney Disease. J Vet Intern Med 2017;31:457-64. [PMID: 28140480 DOI: 10.1111/jvim.14661] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
97 Price EA, Schrier SL. Unexplained aspects of anemia of inflammation. Adv Hematol 2010;2010:508739. [PMID: 20368776 DOI: 10.1155/2010/508739] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
98 Kuragano T, Kitamura K, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura Y, Nakanishi T. ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage. PLoS One 2016;11:e0147328. [PMID: 26933949 DOI: 10.1371/journal.pone.0147328] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
99 Hanudel MR, Chua K, Rappaport M, Gabayan V, Valore E, Goltzman D, Ganz T, Nemeth E, Salusky IB. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Renal Physiol 2016;311:F1369-77. [PMID: 27733366 DOI: 10.1152/ajprenal.00281.2016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
100 Carrilho P. Intravenous iron in heart failure and chronic kidney disease. Nefrología (English Edition) 2021;41:403-11. [DOI: 10.1016/j.nefroe.2021.10.007] [Reference Citation Analysis]
101 Meléndez-Flores JD, Estrada-Bellmann I. Linking chronic kidney disease and Parkinson's disease: a literature review. Metab Brain Dis 2021;36:1-12. [PMID: 32990929 DOI: 10.1007/s11011-020-00623-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Gaweda AE. Markers of iron status in chronic kidney disease. Hemodial Int 2017;21 Suppl 1:S21-7. [PMID: 28328097 DOI: 10.1111/hdi.12556] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
103 Zumbrennen-Bullough K, Babitt JL. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant 2014;29:263-73. [PMID: 24235084 DOI: 10.1093/ndt/gft443] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
104 Casimiro de Almeida J, Lou-Meda R, Olbert M, Seifert M, Weiss G, Wiegerinck ET, Swinkels DW, Solomons NW, Schümann K. The Growth Attainment, Hematological, Iron Status and Inflammatory Profile of Guatemalan Juvenile End-Stage Renal Disease Patients. PLoS One 2015;10:e0140062. [PMID: 26445018 DOI: 10.1371/journal.pone.0140062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
105 Röhrig G, Rappl G, Vahldick B, Kaul I, Schulz RJ. [Serum hepcidin levels in geriatric patients with iron deficiency anemia or anemia of chronic diseases]. Z Gerontol Geriatr 2014;47:51-6. [PMID: 23743883 DOI: 10.1007/s00391-013-0508-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
106 Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87:392-400. [PMID: 22290531 DOI: 10.1002/ajh.23110] [Cited by in Crossref: 114] [Cited by in F6Publishing: 105] [Article Influence: 11.4] [Reference Citation Analysis]
107 Ross SL, Biswas K, Rottman J, Allen JR, Long J, Miranda LP, Winters A, Arvedson TL. Identification of Antibody and Small Molecule Antagonists of Ferroportin-Hepcidin Interaction. Front Pharmacol 2017;8:838. [PMID: 29209212 DOI: 10.3389/fphar.2017.00838] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
108 Jairam A, Das R, Aggarwal PK, Kohli HS, Gupta KL, Sakhuja V, Jha V. Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy. Indian J Nephrol 2010;20:125-31. [PMID: 21072151 DOI: 10.4103/0971-4065.70840] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
109 Lestz RM, Fivush BA, Atkinson MA. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr Nephrol 2014;29:2021-8. [PMID: 24794833 DOI: 10.1007/s00467-014-2820-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
110 Bhamarasuta C, Premratanachai K, Mongkolpinyopat N, Yothapand P, Vejpattarasiri T, Dissayabutra T, Trisiriroj M, Sutayatram S, Buranakarl C. Iron status and erythropoiesis response to darbepoetin alfa in dogs with chronic kidney disease. J Vet Med Sci 2021;83:601-8. [PMID: 33563860 DOI: 10.1292/jvms.20-0574] [Reference Citation Analysis]